Source:http://linkedlifedata.com/resource/pubmed/id/18424792
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
2008-6-16
|
| pubmed:abstractText |
Telavancin is a novel semi-synthetic lipoglycopeptide currently in late-stage clinical development for the treatment of serious infections due to Gram-positive bacteria. The objective of this study was to provide a baseline prospective assessment of its in vitro activity against a large and diverse collection of Gram-positive clinical isolates from Europe and Israel.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
1460-2091
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
62
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
116-21
|
| pubmed:meshHeading |
pubmed-meshheading:18424792-Adult,
pubmed-meshheading:18424792-Aminoglycosides,
pubmed-meshheading:18424792-Anti-Bacterial Agents,
pubmed-meshheading:18424792-Child,
pubmed-meshheading:18424792-Child, Preschool,
pubmed-meshheading:18424792-Europe,
pubmed-meshheading:18424792-Gram-Positive Bacteria,
pubmed-meshheading:18424792-Gram-Positive Bacterial Infections,
pubmed-meshheading:18424792-Humans,
pubmed-meshheading:18424792-Israel,
pubmed-meshheading:18424792-Microbial Sensitivity Tests
|
| pubmed:year |
2008
|
| pubmed:articleTitle |
In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative.
|
| pubmed:affiliation |
Eurofins Medinet, Inc., 13665 Dulles Technology Drive, Suite 200, Herndon, VA, USA.
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|